These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29427486)

  • 1. Management of patients with non-alcoholic steatohepatitis (NASH) in real life.
    Serfaty L
    Liver Int; 2018 Feb; 38 Suppl 1():52-55. PubMed ID: 29427486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists.
    Iacob S; Ester C; Lita M; Ratziu V; Gheorghe L
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):183-9. PubMed ID: 27308649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.
    Driessen S; de Jong VD; van Son KC; Klompenhouwer T; Colardelle Y; Alings M; Moreno C; Anker SD; Castro Cabezas M; Holleboom AG; Grobbee DE; Tushuizen ME
    United European Gastroenterol J; 2023 Sep; 11(7):654-662. PubMed ID: 37563849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
    Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
    Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.
    Polanco-Briceno S; Glass D; Stuntz M; Caze A
    BMC Res Notes; 2016 Mar; 9():157. PubMed ID: 26969270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of physicians' knowledge about pediatric nonalcoholic fatty liver disease in China.
    Gao XY; Yang YF; Li L; Xing YF; Wang YX; Li XY; Yang SH; Wang MY; Fan JG; Wang H
    J Dig Dis; 2024 Jun; 25(6):380-393. PubMed ID: 38992957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease: Status Quo.
    Sporea I; Popescu A; Dumitrașcu D; Brisc C; Nedelcu L; Trifan A; Gheorghe L; Fierbințeanu Braticevici C
    J Gastrointestin Liver Dis; 2018 Dec; 27(4):439-448. PubMed ID: 30574627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
    JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Critical Approach of Guideline Therapeutic Recommendations for NAFLD.
    Djordjevic DB; Zdravkovic M; Nagorni A; Manolis A; Tsioufis C; Lovic D
    Curr Vasc Pharmacol; 2018; 16(3):228-238. PubMed ID: 28676026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
    Arab JP; Dirchwolf M; Álvares-da-Silva MR; Barrera F; Benítez C; Castellanos-Fernandez M; Castro-Narro G; Chavez-Tapia N; Chiodi D; Cotrim H; Cusi K; de Oliveira CPMS; Díaz J; Fassio E; Gerona S; Girala M; Hernandez N; Marciano S; Masson W; Méndez-Sánchez N; Leite N; Lozano A; Padilla M; Panduro A; Paraná R; Parise E; Perez M; Poniachik J; Restrepo JC; Ruf A; Silva M; Tagle M; Tapias M; Torres K; Vilar-Gomez E; Costa Gil JE; Gadano A; Arrese M
    Ann Hepatol; 2020; 19(6):674-690. PubMed ID: 33031970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
    Wessels DH; Rosenberg Z
    World J Hepatol; 2021 Feb; 13(2):233-241. PubMed ID: 33708352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of nonalcoholic fatty liver disease in the Middle East.
    Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
    World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.